SCHEMBL3766823

SCHEMBL3766823

Clc1nc2ccccn2c1-c1ccnc(Nc2cccc(OCCN3CCCC3)c2)n1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AIMP2 Q13155 2/20 0.58
CDK2 P24941 6/20 0.54
CDK4 P11802 1/20 0.48
CCNE1 P24864 1/20 0.48
IGF1R P08069 6/20 0.47
SRC P12931 4/20 0.47
PLK4 O00444 1/20 0.47
CHEK1 O14757 1/20 0.47
PRKD3 O94806 1/20 0.47
LCK P06239 1/20 0.47
CSF1R P07333 1/20 0.47
ROS1 P08922 1/20 0.47
KIT P10721 1/20 0.47
FGFR1 P11362 1/20 0.47
FLT1 P17948 1/20 0.47
FGFR3 P22607 1/20 0.47
MARK3 P27448 1/20 0.47
KDR P35968 1/20 0.47
FLT3 P36888 1/20 0.47
SYK P43405 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3766513 0.86 CDK2 (0.55) CDK2CDK4CCNE1IGF1RSRC
SCHEMBL3762659 0.81 CDK2 (0.56) CDK2CDK4CCNE1IGF1RSRC
SCHEMBL3765120 0.79 CDK2 (0.48) CDK2CDK4CCNE1IGF1RSRC
SCHEMBL1786836 0.79 IGF1R (0.78) IGF1RSRCPRKD3LCKCSF1R
SCHEMBL3761572 0.79 INSR (0.55) AIMP2IGF1REGFRCDK19ALK
SCHEMBL4380756 0.79 AIMP2 (0.66) AIMP2SRCFGFR1EGFRABL1
SCHEMBL3761671 0.79 CDK2 (0.48) CDK2CDK4CCNE1IGF1RSRC
SCHEMBL3760568 0.78 CDK2 (0.74) CDK2CDK4CCNE1IGF1RSRC
SCHEMBL4880015 0.76 AIMP2 (0.57) AIMP2SRCYES1HRH3
SCHEMBL13924599 0.76 SYK (0.65) AIMP2CDK2SRCSYKEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2435436-B1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBVIE INC (US) 2014-07-30 EP disclosed
US-8354422-B2 Pyrimidine inhibitors of kinase activity ABBOTT LABORATORIES INC. (US) 2013-01-15 US disclosed
WO-2010138576-A1 PYRIMIDINE INHIBITORS OF KINASE ACTIVITY ABBOTT LABORATORIES (US) 2010-12-02 WO disclosed
US-20100305126-A1 Pyrimidine Inhibitors of Kinase Activity ABBOTT LABORATORIES (US) 2010-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305126-A1 Pyrimidine Inhibitors of Kinase Activity IGF1R, CDK2, TK1 AIMP2 1453/4885CDK2 2/4885CDK4 21/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.